Johnson & Johnson vs Regeneron Pharmaceuticals Inc — how do they compare? Johnson & Johnson trades at $250.66 (market cap $598.96B), while Regeneron Pharmaceuticals Inc trades at $680.5 (market cap $70.47B). The key difference: Johnson & Johnson is far larger — about 8.5× Regeneron Pharmaceuticals Inc's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | REGN | |
|---|---|---|
Market Cap | $598.96B | $70.47B |
Volume | 6,156,228 | — |
Sector | Health | Health |
52-Week High | $267.24 | $812.27 |
52-Week Low | $164.36 | $545.46 |
Enterprise Value | $631.90B | $64.42B |
Dividend Yield | 2.15% | 0.56% |
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →